Avadel Shareholders Shift Focus to Contingent Payouts Following Acquisition

Avadel's Nasdaq trading ends post-Alkermes buyout. Former shareholders now hold Contingent Value Rights (CVRs) for potential payouts based on FDA approval of LUMRYZ by 2028.

The independent trading of Avadel Pharmaceuticals on the Nasdaq has now formally concluded. This final step follows the company's acquisition by Alkermes, which was finalized in February. For former shareholders, attention turns to a specialized financial instrument whose value is directly tied to future clinical milestones.

Integration Complete, Contingent Rights Activated

With the transaction complete, Avadel no longer operates as a standalone, publicly-traded biopharmaceutical entity. Its full integration into the Alkermes corporate structure is finished. As part of the acquisition agreement, Avadel equity holders received a cash consideration plus a non-transferable Contingent Value Right (CVR). This security entitles them to potential future payments, contingent on specific regulatory achievements.

A Strategic Move into Sleep Medicine

Alkermes's acquisition strengthens its strategic focus on the sleep medicine market, leveraging Avadel's existing infrastructure to expand its footprint in this therapeutic area. The primary driver for the CVR's value is securing U.S. Food and Drug Administration (FDA) approval for LUMRYZ, a treatment for idiopathic hypersomnia in adults. To trigger a payout, this regulatory authorization must be obtained no later than the end of 2028.

Upcoming Clinical Catalyst in 2026

A key near-term event for CVR holders is approaching. Top-line results from the Phase 3 REVITALYZ study are anticipated in the second quarter of 2026. This clinical trial is evaluating the efficacy of extended-release sodium oxybate (LUMRYZ). A successful outcome from this study is considered a critical prerequisite for the subsequent regulatory filing and, consequently, for the CVR to realize its potential monetary value.